Gene-Edited Beagles and Dog Allergies: What the Study Really Shows

Bailey and Alfie were created around one of pet ownership’s most personal barriers: the allergic reaction that can keep someone from living with a dog.

Researchers used CRISPR gene editing to disrupt the gene linked to Can f 1, a major dog-allergy protein. The peer-reviewed paper reports no detectable Can f 1 in the two beagles’ tested saliva, hair or dander samples.

In the paper’s exploratory human test, no detectable skin-prick response to extracts from the edited dogs was reported in one person sensitised to Can f 1. That is remarkable, but one participant and two dogs cannot establish broad clinical benefit.

The result is an interesting proof of concept. It is not evidence that allergy-friendly dogs are ready for family homes, nor that Bailey and Alfie cannot trigger every kind of allergic reaction. Here is what the team changed, what it measured and why “allergy-free dog” would run well ahead of the evidence.

What the researchers changed

The researchers targeted the gene that encodes Can f 1 and introduced a one-base insertion intended to disrupt production of the protein. They then used somatic cell nuclear transfer—the cloning method in which a donor-cell nucleus is placed into an egg whose own nucleus has been removed—to create reconstructed embryos.

The paper reports that 25 reconstructed embryos were transferred to one surrogate. Two female beagles were born on 22 September 2024. This matters because the result was not produced by editing two ordinary puppies after birth: gene editing, donor-cell work, embryo reconstruction, transfer and cloning were all part of the process.

What the tests found

The researchers compared samples from the two edited beagles with samples from non-edited control dogs. Their laboratory tests reported no detectable Can f 1 in the edited dogs’ saliva, hair or dander samples.

They also performed a skin-prick test using dog material in one person who was sensitised to Can f 1. The paper reports no detectable skin-prick response to material from the edited dogs in that one Can f 1-sensitised participant.

That human result is exploratory. One participant cannot establish how people with different dog-allergy profiles would respond, how exposure in a home would compare with a skin-prick test, or whether symptoms would remain lower over time.

Why this does not prove the dogs are allergy-free

Can f 1 is an important dog allergen, but it is not the only one. People can be sensitised to different dog proteins, including allergens other than Can f 1, and an individual’s response depends on their own sensitisation profile.

Removing detectable Can f 1 therefore does not make every other potential dog allergen disappear. The study did not expose a large and varied group of people to the dogs in real homes, measure respiratory symptoms over time or test whether every person with a dog allergy could tolerate them.

“No detectable Can f 1 in the reported samples” is the accurate finding. “Allergy-free dogs” is not.

Were the beagles healthy?

The researchers report routine physical examinations, blood tests and other clinical observations without obvious abnormalities in the two dogs during the period described. They also report whole-genome sequencing and say they found no high-confidence off-target changes attributable to the edit.

Those findings are reassuring within the limits of the study, but two young dogs cannot provide lifetime safety evidence. The paper does not establish long-term outcomes across ageing, breeding or a larger population. It also does not amount to a formal, comprehensive behavioural-welfare assessment.

The careful conclusion is that the two beagles appeared clinically healthy during the reported observation period—not that all future dogs made this way would be unaffected.

The cloning and welfare questions still matter

The headline gene edit is only one part of the experiment. The process also required cell culture, egg manipulation, cloned-embryo production, transfer to a surrogate and pregnancy. Any serious discussion of future use needs to consider the welfare and efficiency of that whole chain, including animals that do not become live births, rather than looking only at the two puppies shown at the end.

The paper says the work was conducted with institutional animal-care approval and refers to regulatory oversight. That tells readers what governance the authors report; it does not settle the broader ethical question of whether creating companion animals for a proposed consumer trait would be justified.

Who funded the research?

The study was funded by Can9. The paper also includes author employment or ownership interests and a patent-related disclosure connected with the work.

Those declarations do not make the findings false. They are relevant context because the research may have commercial applications, and readers should be able to distinguish the published measurements from claims about a future product.

What does this mean for people with dog allergies now?

For now, the study shows that researchers produced two cloned, gene-edited beagles with no detectable Can f 1 in the samples they tested. It does not demonstrate broad clinical benefit, long-term safety or a practical route to an allergy-free pet.

Anyone managing a dog allergy should continue to seek individual medical advice rather than treating a breed label—or an early gene-editing study—as a guarantee. Allergy testing and symptoms are personal, and a response to one dog protein does not describe every possible response to a whole animal or home environment.

The science is worth following. The sales pitch, if one comes, will need much more evidence.

Key limits box

• Two gene-edited dogs were studied.
• Twenty-five reconstructed embryos were transferred to one surrogate.
• No detectable Can f 1 was reported in the tested saliva, hair and dander samples.
• The exploratory human skin-prick comparison involved one Can f 1-sensitised participant.
• Other dog allergens were not removed by this edit.
• The study does not provide lifetime safety, large-population welfare or real-home allergy evidence.
• The work was company-funded and included relevant ownership and patent disclosures.

Sources and update record

• Primary research: “Targeted Genetic Knockout of Can f 1, the Major Allergen in Dogs”, published online 5 August 2026.
• Paper index: PubMed record for the Can f 1 knockout study.
• Allergen context: research on sensitisation to multiple dog allergens.
• Company status: Kindred Companion Sciences says the dogs are not available and the work remains investigational.
• Updated 24 August 2026: This article was expanded with Bailey and Alfie’s names, the precise one-person test result, direct research records and a relevant product bridge.